Form 4: Alkermes Director Cooke Boosts Holdings, Exercises Options

Alkermes plc Director Shane Cooke reported the acquisition of ordinary shares and stock options, alongside a sale for tax withholding purposes.

Summary

• Director Shane Cooke acquired 6,142 ordinary shares on May 21, 2026, following the vesting of a Restricted Stock Unit (RSU) award.
• Cooke disposed of 3,207 ordinary shares at $36.95 each on May 21, 2026, likely to cover tax obligations related to the vesting.
• Cooke was granted 11,538 Non-Qualified Stock Options with an exercise price of $36.98 on May 20, 2026, which vest on May 20, 2027, and expire on May 20, 2036.
• Cooke also received a Restricted Stock Unit award for 5,409 shares on May 20, 2026, which vests in full on May 20, 2027.
• Following these transactions, Cooke directly beneficially owns 106,679 ordinary shares, 11,538 stock options, and 5,409 Restricted Stock Units.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive, reflecting a director's increased equity exposure through new grants and a net increase in ordinary shares, despite a tax-related sale.

Positives

• Acquisition of 6,142 ordinary shares, increasing direct ownership.
• Grant of 11,538 Non-Qualified Stock Options, indicating future potential equity upside.
• Grant of 5,409 Restricted Stock Units, aligning director's interests with shareholders.

Negatives

• Disposal of 3,207 ordinary shares, although this appears to be for tax withholding purposes.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, such as those reported in a Form 4, provide insights into management's perspective on the company's value. While routine for equity compensation, the net increase in potential equity holdings for a director like Shane Cooke can be viewed as a positive signal of confidence in Alkermes' future performance within the biopharmaceutical industry.

Comparison to Industry Standards

• StockSavvy.ai observes that equity compensation, including stock options and restricted stock units, is a standard practice across the biopharmaceutical industry for aligning executive and director interests with shareholder value.
• The vesting schedules and exercise prices are typical for such awards, comparable to practices at peer companies like Biogen or Vertex Pharmaceuticals, which also utilize similar long-term incentive structures to retain talent and incentivize performance.

Related Party Transactions

• The reported transactions involve a director of Alkermes plc, Shane Cooke, acquiring and disposing of company securities, which are inherently related-party transactions as per SEC regulations.

Stakeholder Impact

• Shareholders: The increase in director's equity holdings may signal confidence in the company's future, potentially positively influencing investor sentiment.
• Employees: The use of equity compensation for directors is consistent with broader company practices that often extend to key employees, reinforcing alignment of interests.

Next Steps

• Vesting of 11,538 Non-Qualified Stock Options on May 20, 2027.
• Vesting of 5,409 Restricted Stock Units on May 20, 2027.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to equity compensation and tax withholding. While the director's increased equity exposure is a positive signal, these transactions are not significant enough on their own to warrant a change in investment recommendation. Investors should consider broader company fundamentals and market conditions.

Keywords

Alkermes plc, ALKS, Shane Cooke, Director, Insider Trading, Form 4, Stock Options, Restricted Stock Units, Share Acquisition, Share Disposal, Equity Compensation